FDA vs IVDR Archives

Carlos Galamba

The evolving landscape of Companion Diagnostics (CDx) introduces complexities in regulatory and certification processes. Engaging in IVDR Companion Diagnostic Consulting is essential to ensure a streamlined and compliant journey.

Deciphering Regulatory Nuances: US vs. EU

Historically, CDx devices in the EU were self-certified under the IVDD. A CDx manufacturer may have had experience with the FDA but the regulatory process in the EU is only now emerging.

The EU IVDR defines a CDx as a device which is essential for the safe and effective use of a corresponding medicinal product to identify, before and/or during treatment:

Patients who are most likely to benefit from the corresponding medicinal product
Patients likely to be at increased risk of serious adverse reaction as a result of treatment with a corresponding medicinal product

The FDA’s definition is similar but extends to devices used for “monitoring treatment responses with a particular therapeutic product”. Unlike in the US such devices are not considered companion diagnostics in the EU. Furthermore, the FDA acknowledges a category of devices termed complementary diagnostics. These diagnostics are characterized as tests that pinpoint a group of patients, identified by specific biomarkers, who respond well to a drug. While they assist in evaluating the risk-benefit ratio for individual patients, they aren’t mandatory for drug administration. Within the IVDR framework, complementary diagnostics aren’t explicitly detailed, nor do they have specific prerequisites for CE certification

These nuances are key for any CDx regulatory strategy and for the planning of CDx clinical trials. A specialized IVDR CDx consulting company like MDx CRO can help diagnostic companies and their pharma partners navigate global differences and ensure CDx regulatory compliance.

The EMA Consultation Process

EMA’s guidance stands as a pivotal component in IVDR Companion Diagnostic Consulting. The EMA CDx Assessment Report Template, publicly available, provides a comprehensive blueprint. It is a great source of information for the expectations in CDx submission content, particularly useful for when drafting SSPs and IFUs.

MDx CRO published a comprehensive guide to the CDx consultation process.

The process encompasses:

Declaration of intent.
EMA Rapporteur appointment.
Optional, but highly recommended, pre-submission meeting.
Application submission.
Interactive Q&A phases.
EMA’s final verdict.

Crafting of SSP & IFU with Detail

For successful IVDR CDx certification, the SSP and IFU documents should be meticulously detailed as they are the 2 key documents used during the EMA consultation process.

Diagnostic manufacturers should ensure they include:

Emphasis on scientific validity of the biomarker
Comprehensive detail on performance evaluation, study design descriptions, encompassing both analytical and clinical performance.
Insight into clinical data, detail on device modifications during or after the clinical performance study, and associated impacts, rationale for cut-off point selection and more.

A deep dive into the risk-benefit analysis is pivotal, concentrating on major residual risks and device limitations.

Time Considerations for IVDR CDx Certification

The certification process for CDx under IVDR is extensive. From the initial 3-month EMA notification to the concluding recommendation, the timeline can span 8-18 months. Such extended durations underline the criticality of early preparations. Engaging early with a specialized CDx consulting company can help avoid surprises and streamline the CDx certification journey.

The expertise offered by the notified body can significantly enrich IVDR Companion Diagnostic certification. Early engagements, prior to document submissions, can provide clarity, ensuring alignment with EMA requirements.

Selecting your IVDR CDx Consulting partner

MDx CRO has published a deep dive into the crucial factors to bear in mind when picking an IVD consultant.

In the dynamic realm of CDx, efficient navigation is paramount. If you’re seeking specialized insights into IVDR certification, explore our IVD services. At MDx CRO, our experts offers tailored IVDR Companion Diagnostic Consulting, ensuring optimal integration of CDx within the regulatory framework.

Contact our team today to discuss your CDx product needs!

What is the regulatory process for IVD in Europe, and which are the most important aspects of it? Continue reading to learn more.

The In Vitro Diagnostic (IVD) market in Europe is regulated by a complex framework, and understanding the regulatory process for IVD is crucial for manufacturers looking to bring their products to market. With the implementation of the In Vitro Diagnostic Regulation (IVDR) in 2022, new requirements and conformity assessment routes have been introduced.

In this article, we will discuss the regulatory process for IVD in Europe, highlighting the importance of IVD consultancy and the role MDx CRO can play in developing technical documentation and managing clinical performance studies for IVDs.

1. Overview of the In Vitro Diagnostic Regulation (IVDR)

The IVDR (EU) 2017/746 came into full effect in May 2022, replacing the In Vitro Diagnostic Directive (IVDD) 98/79/EC. The regulation aims to improve patient safety and the performance of IVDs by introducing more stringent requirements for manufacturers. Some of the significant changes introduced by the IVDR include:

A risk-based classification system for IVD devices
Strengthened requirements for clinical evidence
Increased scrutiny of the IVD technical documentation
Increased post-market surveillance (PMS) requirements

2. Risk-based Classification of IVDs

The IVDR introduces a new risk-based classification system, dividing IVDs into four classes (A, B, C, and D) based on their potential risk to patients and public health. This classification system is more aligned with the global risk-based classification approach and helps determine the appropriate conformity assessment route for each IVD device.

3. Conformity Assessment Routes

Under the IVDR, manufacturers are required to follow specific conformity assessment routes based on the classification of their IVD device. The conformity assessment routes include:

Self-certification for Class A non-sterile devices
Assessment by a notified body for Class A sterile, Class B, C, and D devices

Manufacturers must choose a notified body designated under the IVDR to assess their device’s conformity. The notified body will review the technical documentation, conduct a quality management system (QMS) audit, and issue an EU Technical Documentation Assessment Report and an EU QMS Certificate, which are essential for obtaining a CE mark.

4. Technical Documentation

Technical documentation is a crucial aspect of the regulatory process for IVD in Europe. Under the IVDR, manufacturers must maintain comprehensive technical documentation that demonstrates the safety, performance, and compliance of their IVD device. The technical documentation should include:

Device description and specifications
Information about the device’s design and manufacturing process
Pre-clinical, analytical and clinical performance data
Labelling and instructions for use
Risk management documentation
QMS documentation
Post-market surveillance and vigilance data

5. Clinical Evidence and Performance Studies

The IVDR emphasizes the importance of clinical evidence in demonstrating the safety and performance of IVD devices. Manufacturers must conduct clinical performance studies to generate robust clinical evidence that supports their device’s intended purpose, clinical performance claims, and overall safety. The clinical evidence should be periodically updated as part of the post-market surveillance process.

6. Post-Market Surveillance (PMS)

Under the IVDR, manufacturers are required to establish a comprehensive PMS system that monitors the safety, performance, and effectiveness of their IVD device throughout its lifecycle. The PMS system should be capable of identifying and addressing potential risks, non-conformities, and adverse events.

Manufacturers must also establish a Periodic Safety Update Report (PSUR) to provide a summary of the PMS data and any necessary corrective actions.

7. The Role of IVD Consultancy and CRO

Navigating the regulatory process for IVD in Europe can be a complex and time-consuming task. Partnering with an experienced IVD consultancy can significantly streamline the process, ensuring compliance with the IVDR and facilitating a successful market entry. IVD consultancies, such as MDx CRO, offer invaluable support in various areas, including:

Developing technical documentation
Managing clinical performance studies
Designing and implementing a robust QMS
Guiding through the risk management process
Assisting with post-market surveillance and vigilance activities

8. How MDx CRO Can Help

MDx CRO is a leading IVD consultancy and IVD CRO that specializes in helping manufacturers navigate the regulatory process for IVD in Europe. Our team of experts has extensive experience in developing technical documentation and managing clinical performance studies for IVDs, ensuring compliance with the IVDR.

We offer the following services:

Technical documentation development: Our team will work closely with you to create comprehensive technical documentation that demonstrates your IVD device’s safety, performance, and compliance with the IVDR.
Clinical performance study management: We design and manage clinical performance studies tailored to your IVD device, generating robust clinical evidence that supports your device’s intended purpose and clinical performance claims.
Post-market surveillance support: We assist manufacturers in establishing a comprehensive PMS system, ensuring continuous monitoring of the safety and performance of your IVD device throughout its lifecycle.

Regulatory Process for IVD: Conclusion

Understanding the regulatory process for IVD in Europe is crucial for manufacturers looking to bring their products to market successfully. The IVDR has introduced new requirements and conformity assessment routes that manufacturers must comply with to ensure patient safety and the performance of their IVD devices.

Partnering with an experienced IVD consultancy like MDx CRO can significantly streamline the process, providing invaluable support in developing technical documentation, managing clinical performance studies, and ensuring compliance with the IVDR.

Are you in need of expert guidance and support to navigate the regulatory process for IVD in Europe? Contact MDx CRO today to learn more about our IVD consultancy services and how we can help you successfully bring your IVD device to market.

FAQs

What are the key changes introduced by the In Vitro Diagnostic Regulation (IVDR) in Europe?

The IVDR has introduced several significant changes to the regulatory process for IVD in Europe. Some of the key changes include:

A new risk-based classification system for IVD devices, dividing them into four classes (A, B, C, and D) based on their potential risk to patients and public health.
More stringent requirements for clinical evidence, emphasizing the importance of conducting clinical performance studies to generate robust clinical data.
Increased scrutiny of the IVD technical documentation to ensure the safety, performance, and compliance of IVD devices.
Enhanced post-market surveillance (PMS) requirements, mandating manufacturers to establish a comprehensive PMS system that monitors the safety and performance of their IVD devices throughout their lifecycle.

How can an IVD consultancy like MDx CRO help manufacturers navigate the regulatory process for IVD in Europe?

MDx CRO, a leading IVD consultancy, offers expert guidance and support to help manufacturers navigate the complex regulatory process for IVD in Europe. Our services include:

Developing technical documentation that demonstrates the safety, performance, and compliance of IVD devices according to the IVDR requirements.
Designing and managing clinical performance studies tailored to the specific IVD device, generating robust clinical evidence to support its intended purpose and clinical performance claims.
Assisting with the establishment of a comprehensive post-market surveillance system, ensuring continuous monitoring and addressing any potential risks, non-conformities, or adverse events throughout the device’s lifecycle.

By partnering with MDx CRO, manufacturers can ensure compliance with the IVDR and successfully bring their IVD devices to the European market.

Tag: FDA vs IVDR

Navigating the IVDR CDx Certification Pathway